Inhibition of the CD47–SIRPα axis by TTI-621 to treat relapsed or refractory mycosis fungoides or Sézary syndrome

Abstract

In a large, retrospective follow-up trial from the Cutaneous Lymphoma International Consortium, it was shown that among both US and non-US centres, there was a large treatment heterogeneity in advanced mycosis fungoides and Sézary syndrome.1 The differences in treatment were not associated with a difference in survival between US and non-US centres; however, the data showed that chemotherapy as first treatment was associated with a higher risk of death or change in therapy. Therefore, other therapeutic options should preferably serve as the first treatment approach,1 and it is agreed worldwide that new relevant targets for monoclonal antibody therapy are needed.